Last reviewed · How we verify
Placebo PO QD
Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.
Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect. Used for Clinical trial control arm (specific indication depends on the trial protocol).
At a glance
| Generic name | Placebo PO QD |
|---|---|
| Sponsor | Priovant Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials. Any observed therapeutic benefit derives from patient expectation, the clinical encounter, and natural disease progression rather than direct molecular action. Placebo is essential for establishing the true efficacy of investigational drugs by comparison.
Approved indications
- Clinical trial control arm (specific indication depends on the trial protocol)
Common side effects
- Placebo effect (perceived symptom improvement without active drug)
- Nocebo effect (perceived adverse events without active drug)
Key clinical trials
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (PHASE3)
- Testing Obeticholic Acid for Familial Adenomatous Polyposis (PHASE2)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2, PHASE3)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1, PHASE2)
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |